EyeGene (A185490) Stock Overview
Engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
A185490 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
EyeGene Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩1,460.00 |
| 52 Week High | ₩3,950.00 |
| 52 Week Low | ₩1,420.00 |
| Beta | 1.05 |
| 1 Month Change | -14.72% |
| 3 Month Change | -19.02% |
| 1 Year Change | -45.83% |
| 3 Year Change | -76.94% |
| 5 Year Change | -85.40% |
| Change since IPO | -86.63% |
Recent News & Updates
Recent updates
EyeGene (KOSDAQ:185490) Is In A Good Position To Deliver On Growth Plans
Nov 27
Health Check: How Prudently Does EyeGene (KOSDAQ:185490) Use Debt?
Jul 26Does EyeGene (KOSDAQ:185490) Have A Healthy Balance Sheet?
Mar 29EyeGene's (KOSDAQ:185490) Stock Price Has Reduced 51% In The Past Five Years
Feb 01
Is EyeGene (KOSDAQ:185490) Using Debt In A Risky Way?
Dec 07Shareholder Returns
| A185490 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -7.8% | -5.3% | 0.3% |
| 1Y | -45.8% | 48.4% | 96.4% |
Return vs Industry: A185490 underperformed the KR Biotechs industry which returned 48.4% over the past year.
Return vs Market: A185490 underperformed the KR Market which returned 96.4% over the past year.
Price Volatility
| A185490 volatility | |
|---|---|
| A185490 Average Weekly Movement | 14.4% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A185490's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A185490's weekly volatility has increased from 9% to 14% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 49 | Won-Il Yoo | www.eyegene.co.kr |
EyeGene Inc. engages in the research and development of biopharmaceutical drugs for the treatment and prevention of age-related diseases in South Korea. Its product pipeline comprises EG-Mirotin, which has completed Phase 2a clinical trial to treat diabetic retinopathy; EG-Decorin which completed Phase 2 clinical trial for the treatment of pressure ulcers and wound healing; and EG-Myocin, which has completed Phase II clinical trials for the treatment of myocardial ischemia/reperfusion injury. It also develops EG-HZ, which has completed phase 1 clinical trial for the treatment of herpes zoster; EG-HPV which completed Phase 1 clinical trial to treat cervical cancer; EG-COVID that is in phase I clinical trial for the treatment of covid; and EG-TB for the tuberculosis vaccine and is in preclinical trial.
EyeGene Inc. Fundamentals Summary
| A185490 fundamental statistics | |
|---|---|
| Market cap | ₩63.12b |
| Earnings (TTM) | -₩9.67b |
| Revenue (TTM) | ₩4.10b |
Is A185490 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A185490 income statement (TTM) | |
|---|---|
| Revenue | ₩4.10b |
| Cost of Revenue | ₩2.92b |
| Gross Profit | ₩1.19b |
| Other Expenses | ₩10.85b |
| Earnings | -₩9.67b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -223.60 |
| Gross Margin | 28.89% |
| Net Profit Margin | -235.54% |
| Debt/Equity Ratio | 0% |
How did A185490 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 03:41 |
| End of Day Share Price | 2026/02/03 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
EyeGene Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiyong Lee | Shinhan Investment Corp. |